Literature DB >> 3325203

Homogeneous immunoglobulins in the sera of lung carcinoma patients receiving cytotoxic chemotherapy--detection with the use of isoelectric focusing and immunoblotting.

H Haas1, A Lange, M Schlaak.   

Abstract

Using isoelectric focusing (IEF) with immunoblotting, we have analysed serum immunoglobulins of 15 lung cancer patients on cytotoxic chemotherapy. In five of the patients homogeneous immunoglobulins were found which appeared between 9 and 18 months after beginning of treatment and were monoclonal in two and oligoclonal in three cases. These abnormalities were only partially shown by zonal electrophoresis with immunofixation and not detected by immune electrophoresis. Examination of 10 normal and 10 myeloma sera by the three techniques in parallel confirmed the competence and sensitivity of IEF with immunoblotting in detecting homogeneous immunoglobulins. Thus, this method provides a valuable tool for investigating an abnormal regulation of the immunoglobulin synthesis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3325203      PMCID: PMC1542184     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  15 in total

1.  Isoelectric focusing and reverse immunoblotting of autoantibodies against high molecular weight antigens.

Authors:  D I Stott; J McLearie
Journal:  Immunol Invest       Date:  1986-04       Impact factor: 3.657

2.  Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy.

Authors:  T E Starzl; M A Nalesnik; K A Porter; M Ho; S Iwatsuki; B P Griffith; J T Rosenthal; T R Hakala; B W Shaw; R L Hardesty
Journal:  Lancet       Date:  1984-03-17       Impact factor: 79.321

3.  The application of isoelectric focusing to routine screening for paraproteinaemia.

Authors:  D Sinclair; D S Kumararatne; J B Forrester; A Lamont; D I Stott
Journal:  J Immunol Methods       Date:  1983-11-11       Impact factor: 2.303

4.  Semi-automatic analysis of proteins and protein complexes by automated enzyme immunoassay after separation by high-performance gel-permeation chromatography. Size distribution of C3-IgG complexes.

Authors:  U Holmskov-Nielsen; K Erb; J C Jensenius
Journal:  J Chromatogr       Date:  1984-08-03

5.  India ink staining of proteins on nitrocellulose paper.

Authors:  K Hancock; V C Tsang
Journal:  Anal Biochem       Date:  1983-08       Impact factor: 3.365

6.  Isoelectric focusing of human IgA and secretory proteins using thin layer agarose gels and nitrocellulose capillary blotting.

Authors:  K B Elkon
Journal:  J Immunol Methods       Date:  1984-02-10       Impact factor: 2.303

Review 7.  Depressed immunity and the development of cancer.

Authors:  I Penn
Journal:  Clin Exp Immunol       Date:  1981-12       Impact factor: 4.330

Review 8.  The search for antibodies with molecular uniformity.

Authors:  R M Krause
Journal:  Adv Immunol       Date:  1970       Impact factor: 3.543

9.  Lymphoproliferative disorders in cardiac transplant recipients are multiclonal lymphomas.

Authors:  M L Cleary; J Sklar
Journal:  Lancet       Date:  1984-09-01       Impact factor: 79.321

10.  Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathologic, and virologic findings and implications for therapy.

Authors:  D W Hanto; K J Gajl-Peczalska; G Frizzera; D C Arthur; H H Balfour; K McClain; R L Simmons; J S Najarian
Journal:  Ann Surg       Date:  1983-09       Impact factor: 12.969

View more
  2 in total

1.  Oligo-monoclonal immunoglobulins frequently develop during concurrent cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections in patients after renal transplantation.

Authors:  E Drouet; C Chapuis-Cellier; S Bosshard; C Verniol; A Niveleau; J L Touraine; J L Garnier
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  Do infections induce monoclonal immunoglobulin components?

Authors:  H Haas; S Anders; G W Bornkamm; E Mannweiler; H Schmitz; J Radl; M Schlaak
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.